Twin Capital Management Inc. Acquires New Position in Biogen Inc. $BIIB

Twin Capital Management Inc. bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 1st quarter, HoldingsChannel.com reports. The fund bought 4,430 shares of the biotechnology company’s stock, valued at approximately $812,000.

Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Biogen in the 4th quarter valued at approximately $464,408,000. Boston Partners purchased a new stake in shares of Biogen during the fourth quarter worth $302,815,000. Fred Alger Management LLC raised its stake in shares of Biogen by 39,074.8% in the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after acquiring an additional 796,735 shares in the last quarter. Employees Provident Fund Board acquired a new stake in shares of Biogen in the fourth quarter valued at $123,931,000. Finally, Orion Porfolio Solutions LLC boosted its holdings in Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after purchasing an additional 509,809 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Synapticure launched a new virtual ataxia care program with Biogen support, highlighting continued investment in Biogen’s neurology franchise and potentially broadening patient access. Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
• Positive Sentiment: Biogen appointed Michael J. Parini as Chief Legal Officer, a seasoned biopharma leader whose compliance and strategic experience may support execution and governance. Biogen Appoints Michael J. Parini as Chief Legal Officer
• Neutral Sentiment: Analysts offered fresh commentary on Biogen, but the headline did not include a clear new rating or target change, so the stock impact appears limited. Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Biogen (BIIB)
• Negative Sentiment: Recent Alzheimer’s-related data on diranersen and tau-targeting ASO programs raised questions about dosing and trial progress, which weighed on sentiment toward Biogen’s pipeline. Biogen shares slide as diranersen data raise dosing question
• Negative Sentiment: Investors reacted negatively to detailed diranersen Alzheimer’s study data, as the results reinforced concerns about a prior phase II setback despite plans to move ahead. Biogen Shares Decline After Detailed Diranersen Alzheimer’s Study Data

Biogen Trading Up 5.9%

BIIB opened at $208.92 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen Inc. has a one year low of $121.05 and a one year high of $219.72. The company has a market cap of $30.84 billion, a P/E ratio of 22.42 and a beta of 0.16. The business’s 50-day simple moving average is $199.18 and its 200-day simple moving average is $188.88.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts expect that Biogen Inc. will post 13.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BIIB has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their target price on Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. UBS Group raised Biogen from a “neutral” rating to a “buy” rating and increased their price target for the company from $185.00 to $225.00 in a research report on Wednesday, April 22nd. HC Wainwright reiterated a “buy” rating on shares of Biogen in a research note on Thursday, May 14th. HSBC reissued a “reduce” rating and set a $157.00 price objective on shares of Biogen in a research report on Monday, July 6th. Finally, The Goldman Sachs Group upped their target price on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $220.04.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.